#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-11	Classifying	_
1-2	12-15	and	_
1-3	16-30	Characterizing	_
1-4	31-39	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
1-5	40-43	Use	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
1-6	44-52	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
1-7	53-57	with	_
1-8	58-62	High	_
1-9	63-71	Accuracy	_
1-10	72-77	Using	_
1-11	78-85	Machine	_
1-12	86-94	Learning	_
1-13	95-98	and	_
1-14	99-112	Resting-State	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-15	113-117	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-16	118-127	Cigarette	_
1-17	128-135	smoking	_
1-18	136-145	continues	_
1-19	146-148	to	_
1-20	149-151	be	_
1-21	152-153	a	_
1-22	154-161	leading	_
1-23	162-167	cause	_
1-24	168-170	of	_
1-25	171-182	preventable	_
1-26	183-192	morbidity	_
1-27	193-196	and	_
1-28	197-206	mortality	_
1-29	207-208	.	_

2-1	209-217	Although	_
2-2	218-221	the	_
2-3	222-230	majority	_
2-4	231-233	of	_
2-5	234-241	smokers	_
2-6	242-248	report	_
2-7	249-255	making	_
2-8	256-257	a	_
2-9	258-262	quit	_
2-10	263-270	attempt	_
2-11	271-273	in	_
2-12	274-277	the	_
2-13	278-282	past	_
2-14	283-287	year	_
2-15	288-289	,	_
2-16	290-297	smoking	_
2-17	298-307	cessation	_
2-18	308-313	rates	_
2-19	314-320	remain	_
2-20	321-327	modest	_
2-21	328-329	.	_

3-1	330-334	Thus	_
3-2	335-336	,	_
3-3	337-347	developing	_
3-4	348-356	accurate	_
3-5	357-358	,	_
3-6	359-370	data-driven	_
3-7	371-378	methods	_
3-8	379-383	that	_
3-9	384-387	can	_
3-10	388-396	classify	_
3-11	397-400	and	_
3-12	401-413	characterize	_
3-13	414-417	the	_
3-14	418-424	neural	_
3-15	425-433	features	_
3-16	434-436	of	_
3-17	437-445	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
3-18	446-449	use	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
3-19	450-458	disorder	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
3-20	459-460	(	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
3-21	461-464	NUD	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
3-22	465-466	)	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
3-23	467-472	would	_
3-24	473-475	be	_
3-25	476-477	a	_
3-26	478-486	powerful	_
3-27	487-495	clinical	_
3-28	496-500	tool	_
3-29	501-505	that	_
3-30	506-511	could	_
3-31	512-515	aid	_
3-32	516-518	in	_
3-33	519-529	optimizing	_
3-34	530-539	treatment	_
3-35	540-551	development	_
3-36	552-555	and	_
3-37	556-561	guide	_
3-38	562-571	treatment	_
3-39	572-585	modifications	_
3-40	586-587	.	_

4-1	588-592	This	_
4-2	593-606	investigation	_
4-3	607-614	applied	_
4-4	615-629	support-vector	_
4-5	630-643	machine-based	_
4-6	644-658	classification	_
4-7	659-661	to	_
4-8	662-675	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
4-9	676-686	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
4-10	687-699	connectivity	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
4-11	700-701	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
4-12	702-706	rsFC	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
4-13	707-708	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
4-14	709-713	data	_
4-15	714-718	from	_
4-16	719-730	individuals	_
4-17	731-740	diagnosed	_
4-18	741-745	with	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
4-19	746-749	NUD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-20	750-751	(	_
4-21	752-757	n=108	_
4-22	758-759	;	_
4-23	760-762	63	_
4-24	763-768	males	_
4-25	769-770	)	_
4-26	771-774	and	_
4-27	775-782	matched	_
4-28	783-793	nonsmoking	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-29	794-802	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-30	803-804	(	_
4-31	805-810	n=108	_
4-32	811-812	;	_
4-33	813-815	63	_
4-34	816-821	males	_
4-35	822-823	)	_
4-36	824-827	and	_
4-37	828-844	multidimensional	_
4-38	845-852	scaling	http://maven.renci.org/NeuroBridge/neurobridge#Scale
4-39	853-854	(	_
4-40	855-858	MDS	_
4-41	859-860	)	_
4-42	861-863	to	_
4-43	864-873	visualize	_
4-44	874-877	the	_
4-45	878-891	heterogeneity	_
4-46	892-894	of	_
4-47	895-898	NUD	_
4-48	899-901	in	_
4-49	902-912	individual	_
4-50	913-920	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
4-51	921-926	based	_
4-52	927-929	on	_
4-53	930-934	rsFC	_
4-54	935-943	measures	_
4-55	944-945	.	_

5-1	946-959	Machine-based	_
5-2	960-968	learning	_
5-3	969-975	models	_
5-4	976-986	identified	_
5-5	987-991	five	_
5-6	992-999	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-7	1000-1005	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-8	1006-1014	networks	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-9	1015-1016	(	_
5-10	1017-1021	RSNs	_
5-11	1022-1023	)	_
5-12	1024-1028	that	_
5-13	1029-1035	played	_
5-14	1036-1037	a	_
5-15	1038-1042	role	_
5-16	1043-1045	in	_
5-17	1046-1060	distinguishing	_
5-18	1061-1068	smokers	_
5-19	1069-1073	from	_
5-20	1074-1082	controls	_
5-21	1083-1084	:	_
5-22	1085-1088	the	_
5-23	1089-1098	posterior	_
5-24	1099-1102	and	_
5-25	1103-1111	anterior	_
5-26	1112-1119	default	_
5-27	1120-1124	mode	_
5-28	1125-1133	networks	_
5-29	1134-1135	,	_
5-30	1136-1139	the	_
5-31	1140-1152	sensorimotor	_
5-32	1153-1160	network	_
5-33	1161-1162	,	_
5-34	1163-1166	the	_
5-35	1167-1175	salience	_
5-36	1176-1183	network	_
5-37	1184-1185	,	_
5-38	1186-1189	and	_
5-39	1190-1193	the	_
5-40	1194-1199	right	_
5-41	1200-1209	executive	_
5-42	1210-1217	control	_
5-43	1218-1225	network	_
5-44	1226-1227	.	_

6-1	1228-1231	The	_
6-2	1232-1246	classification	_
6-3	1247-1253	method	_
6-4	1254-1265	constructed	_
6-5	1266-1277	classifiers	_
6-6	1278-1282	with	_
6-7	1283-1285	an	_
6-8	1286-1293	average	_
6-9	1294-1301	correct	_
6-10	1302-1316	classification	_
6-11	1317-1321	rate	_
6-12	1322-1324	of	_
6-13	1325-1329	88.1	_
6-14	1330-1331	%	_
6-15	1332-1335	and	_
6-16	1336-1338	an	_
6-17	1339-1346	average	_
6-18	1347-1351	area	_
6-19	1352-1357	under	_
6-20	1358-1361	the	_
6-21	1362-1367	curve	_
6-22	1368-1370	of	_
6-23	1371-1375	0.93	_
6-24	1376-1377	.	_

7-1	1378-1386	Compared	_
7-2	1387-1389	to	_
7-3	1390-1398	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-4	1399-1400	,	_
7-5	1401-1412	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
7-6	1413-1417	with	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
7-7	1418-1421	NUD	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
7-8	1422-1425	had	_
7-9	1426-1432	weaker	_
7-10	1433-1443	functional	_
7-11	1444-1456	connectivity	_
7-12	1457-1465	measures	_
7-13	1466-1472	within	_
7-14	1473-1478	these	_
7-15	1479-1487	networks	_
7-16	1488-1489	(	_
7-17	1490-1491	p	_
7-18	1492-1493	<	_
7-19	1494-1498	0.05	_
7-20	1499-1500	,	_
7-21	1501-1506	false	_
7-22	1507-1516	discovery	_
7-23	1517-1521	rate	_
7-24	1522-1531	corrected	_
7-25	1532-1533	)	_
7-26	1534-1535	.	_

8-1	1536-1543	Further	_
8-2	1544-1545	,	_
8-3	1546-1549	MDS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
8-4	1550-1563	visualization	_
8-5	1564-1576	demonstrated	_
8-6	1577-1581	that	_
8-7	1582-1590	controls	_
8-8	1591-1595	were	_
8-9	1596-1603	similar	_
8-10	1604-1606	to	_
8-11	1607-1611	each	_
8-12	1612-1617	other	_
8-13	1618-1619	;	_
8-14	1620-1627	whereas	_
8-15	1628-1629	,	_
8-16	1630-1641	individuals	_
8-17	1642-1646	with	_
8-18	1647-1650	NUD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
8-19	1651-1654	had	_
8-20	1655-1659	less	_
8-21	1660-1670	similarity	_
8-22	1671-1673	to	_
8-23	1674-1682	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-24	1683-1686	and	_
8-25	1687-1689	to	_
8-26	1690-1695	other	_
8-27	1696-1707	individuals	_
8-28	1708-1712	with	_
8-29	1713-1716	NUD	_
8-30	1717-1718	.	_

9-1	1719-1722	Our	_
9-2	1723-1731	findings	_
9-3	1732-1737	build	_
9-4	1738-1742	upon	_
9-5	1743-1751	previous	_
9-6	1752-1762	literature	_
9-7	1763-1776	demonstrating	_
9-8	1777-1781	that	_
9-9	1782-1798	machine-learning	_
9-10	1799-1804	based	_
9-11	1805-1815	approaches	_
9-12	1816-1818	to	_
9-13	1819-1830	classifying	_
9-14	1831-1835	rsFC	_
9-15	1836-1840	data	_
9-16	1841-1846	offer	_
9-17	1847-1848	a	_
9-18	1849-1857	valuable	_
9-19	1858-1867	technique	_
9-20	1868-1870	to	_
9-21	1871-1884	understanding	_
9-22	1885-1898	network-level	_
9-23	1899-1910	differences	_
9-24	1911-1913	in	_
9-25	1914-1930	nicotine-related	_
9-26	1931-1943	neurobiology	_
9-27	1944-1947	and	_
9-28	1948-1954	extend	_
9-29	1955-1963	previous	_
9-30	1964-1972	findings	_
9-31	1973-1975	by	_
9-32	1976-1985	improving	_
9-33	1986-2000	classification	_
9-34	2001-2009	accuracy	_
9-35	2010-2013	and	_
9-36	2014-2027	demonstrating	_
9-37	2028-2031	the	_
9-38	2032-2045	heterogeneity	_
9-39	2046-2048	in	_
9-40	2049-2053	RSNs	_
9-41	2054-2056	of	_
9-42	2057-2068	individuals	_
9-43	2069-2073	with	_
9-44	2074-2077	NUD	_
9-45	2078-2079	.	_

10-1	2080-2087	METHODS	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
10-2	2088-2100	Participants	_
10-3	2101-2113	Participants	_
10-4	2114-2118	were	_
10-5	2119-2127	selected	_
10-6	2128-2132	from	_
10-7	2133-2134	a	_
10-8	2135-2141	larger	_
10-9	2142-2148	cohort	_
10-10	2149-2151	of	_
10-11	2152-2163	individuals	_
10-12	2164-2168	with	_
10-13	2169-2172	NUD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
10-14	2173-2176	and	_
10-15	2177-2188	non-smoking	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-16	2189-2197	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-17	2198-2203	based	_
10-18	2204-2206	on	_
10-19	2207-2218	demographic	_
10-20	2219-2234	characteristics	_
10-21	2235-2236	(	_
10-22	2237-2240	for	_
10-23	2241-2249	matching	_
10-24	2250-2258	purposes	_
10-25	2259-2260	)	_
10-26	2261-2264	and	_
10-27	2265-2269	head	_
10-28	2270-2276	motion	_
10-29	2277-2280	and	_
10-30	2281-2289	included	_
10-31	2290-2293	108	_
10-32	2294-2305	individuals	_
10-33	2306-2310	with	_
10-34	2311-2314	NUD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
10-35	2315-2316	(	_
10-36	2317-2319	63	_
10-37	2320-2325	males	_
10-38	2326-2327	)	_
10-39	2328-2331	and	_
10-40	2332-2335	108	_
10-41	2336-2351	demographically	_
10-42	2352-2355	and	_
10-43	2356-2362	motion	_
10-44	2363-2370	matched	_
10-45	2371-2382	non-smoking	_
10-46	2383-2391	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-47	2392-2393	(	_
10-48	2394-2396	63	_
10-49	2397-2402	males	_
10-50	2403-2404	)	_
10-51	2405-2406	.	_

11-1	2407-2410	All	_
11-2	2411-2423	participants	_
11-3	2424-2433	completed	_
11-4	2434-2436	an	_
11-5	2437-2444	initial	_
11-6	2445-2454	telephone	_
11-7	2455-2461	screen	_
11-8	2462-2470	followed	_
11-9	2471-2473	by	_
11-10	2474-2476	an	_
11-11	2477-2486	in-person	_
11-12	2487-2496	screening	_
11-13	2497-2500	and	_
11-14	2501-2509	informed	_
11-15	2510-2517	consent	_
11-16	2518-2525	session	_
11-17	2526-2527	.	_

12-1	2528-2539	Individuals	_
12-2	2540-2544	with	_
12-3	2545-2546	a	_
12-4	2547-2554	current	_
12-5	2555-2561	DSM-IV	_
12-6	2562-2566	Axis	_
12-7	2567-2568	I	_
12-8	2569-2578	diagnoses	_
12-9	2579-2580	(	_
12-10	2581-2586	other	_
12-11	2587-2591	than	_
12-12	2592-2595	NUD	_
12-13	2596-2598	in	_
12-14	2599-2606	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
12-15	2607-2608	)	_
12-16	2609-2610	,	_
12-17	2611-2619	lifetime	_
12-18	2620-2627	history	_
12-19	2628-2630	of	_
12-20	2631-2635	head	_
12-21	2636-2642	injury	_
12-22	2643-2647	with	_
12-23	2648-2652	loss	_
12-24	2653-2655	of	_
12-25	2656-2669	consciousness	_
12-26	2670-2673	for	_
12-27	2674-2678	more	_
12-28	2679-2683	than	_
12-29	2684-2685	3	_
12-30	2686-2693	minutes	_
12-31	2694-2695	,	_
12-32	2696-2713	contraindications	_
12-33	2714-2717	for	_
12-34	2718-2721	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
12-35	2722-2723	,	_
12-36	2724-2727	and	_
12-37	2728-2738	clinically	_
12-38	2739-2750	significant	_
12-39	2751-2758	medical	_
12-40	2759-2769	conditions	_
12-41	2770-2774	were	_
12-42	2775-2783	excluded	_
12-43	2784-2785	.	_

13-1	2786-2789	The	_
13-2	2790-2795	study	_
13-3	2796-2804	protocol	_
13-4	2805-2808	was	_
13-5	2809-2817	executed	_
13-6	2818-2820	in	_
13-7	2821-2831	accordance	_
13-8	2832-2836	with	_
13-9	2837-2840	the	_
13-10	2841-2850	standards	_
13-11	2851-2853	of	_
13-12	2854-2857	the	_
13-13	2858-2869	Declaration	_
13-14	2870-2872	of	_
13-15	2873-2881	Helsinki	_
13-16	2882-2885	and	_
13-17	2886-2894	approved	_
13-18	2895-2897	by	_
13-19	2898-2901	the	_
13-20	2902-2912	University	_
13-21	2913-2915	of	_
13-22	2916-2928	Pennsylvania	_
13-23	2929-2942	Institutional	_
13-24	2943-2949	Review	_
13-25	2950-2955	Board	_
13-26	2956-2957	.	_

14-1	2958-2966	Measures	_
14-2	2967-2968	A	_
14-3	2969-2976	general	_
14-4	2977-2989	demographics	_
14-5	2990-3003	questionnaire	_
14-6	3004-3012	assessed	_
14-7	3013-3024	participant	_
14-8	3025-3026	’	_
14-9	3027-3028	s	_
14-10	3029-3039	biological	_
14-11	3040-3043	sex	_
14-12	3044-3045	,	_
14-13	3046-3049	age	_
14-14	3050-3051	,	_
14-15	3052-3056	race	_
14-16	3057-3058	,	_
14-17	3059-3062	and	_
14-18	3063-3068	years	_
14-19	3069-3071	of	_
14-20	3072-3081	education	_
14-21	3082-3083	(	_
14-22	3084-3089	Table	_
14-23	3090-3091	1	_
14-24	3092-3093	)	_
14-25	3094-3095	.	_

15-1	3096-3099	The	_
15-2	3100-3118	Mini-International	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale
15-3	3119-3135	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale
15-4	3136-3145	Interview	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale
15-5	3146-3154	assessed	_
15-6	3155-3162	current	_
15-7	3163-3169	DSM-IV	_
15-8	3170-3179	diagnosis	_
15-9	3180-3182	of	_
15-10	3183-3192	substance	_
15-11	3193-3203	dependence	_
15-12	3204-3209	other	_
15-13	3210-3214	than	_
15-14	3215-3223	nicotine	_
15-15	3224-3227	and	_
15-16	3228-3235	current	_
15-17	3236-3247	psychiatric	_
15-18	3248-3256	symptoms	_
15-19	3257-3258	.	_

16-1	3259-3262	The	_
16-2	3263-3273	Fagerström	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
16-3	3274-3278	Test	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
16-4	3279-3282	for	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
16-5	3283-3291	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
16-6	3292-3302	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
16-7	3303-3304	(	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
16-8	3305-3309	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
16-9	3310-3311	)	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
16-10	3312-3320	measured	_
16-11	3321-3329	severity	_
16-12	3330-3332	of	_
16-13	3333-3341	nicotine	_
16-14	3342-3352	dependence	_
16-15	3353-3358	among	_
16-16	3359-3370	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
16-17	3371-3375	with	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
16-18	3376-3379	NUD	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
16-19	3380-3381	.	_

17-1	3382-3393	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
17-2	3394-3398	with	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
17-3	3399-3402	NUD	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
17-4	3403-3407	also	_
17-5	3408-3416	reported	_
17-6	3417-3419	on	_
17-7	3420-3423	the	_
17-8	3424-3430	number	_
17-9	3431-3433	of	_
17-10	3434-3444	cigarettes	_
17-11	3445-3451	smoked	_
17-12	3452-3455	per	_
17-13	3456-3459	day	_
17-14	3460-3461	(	_
17-15	3462-3465	CPD	_
17-16	3466-3467	)	_
17-17	3468-3469	,	_
17-18	3470-3476	number	_
17-19	3477-3479	of	_
17-20	3480-3485	years	_
17-21	3486-3488	of	_
17-22	3489-3496	smoking	_
17-23	3497-3498	,	_
17-24	3499-3502	and	_
17-25	3503-3506	any	_
17-26	3507-3512	other	_
17-27	3513-3522	substance	_
17-28	3523-3526	use	_
17-29	3527-3531	over	_
17-30	3532-3535	the	_
17-31	3536-3540	past	_
17-32	3541-3543	30	_
17-33	3544-3548	days	_
17-34	3549-3550	.	_

18-1	3551-3556	Urine	_
18-2	3557-3561	drug	_
18-3	3562-3569	screens	_
18-4	3570-3578	verified	_
18-5	3579-3582	the	_
18-6	3583-3590	absence	_
18-7	3591-3593	of	_
18-8	3594-3601	illicit	_
18-9	3602-3607	drugs	_
18-10	3608-3610	in	_
18-11	3611-3614	all	_
18-12	3615-3623	subjects	_
18-13	3624-3627	and	_
18-14	3628-3631	the	_
18-15	3632-3639	absence	_
18-16	3640-3642	of	_
18-17	3643-3651	nicotine	_
18-18	3652-3655	and	_
18-19	3656-3659	its	_
18-20	3660-3665	major	_
18-21	3666-3676	metabolite	_
18-22	3677-3678	,	_
18-23	3679-3687	cotinine	_
18-24	3688-3689	,	_
18-25	3690-3692	in	_
18-26	3693-3701	controls	_
18-27	3702-3703	.	_

19-1	3704-3714	Procedures	_
19-2	3715-3720	Image	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
19-3	3721-3732	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
19-4	3733-3748	High-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
19-5	3749-3759	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
19-6	3760-3763	and	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
19-7	3764-3777	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
19-8	3778-3783	blood	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
19-9	3784-3790	oxygen	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
19-10	3791-3806	level-dependent	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
19-11	3807-3808	(	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
19-12	3809-3813	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
19-13	3814-3815	)	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
19-14	3816-3826	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
19-15	3827-3835	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
19-16	3836-3845	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
19-17	3846-3853	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
19-18	3854-3855	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
19-19	3856-3860	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
19-20	3861-3862	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
19-21	3863-3867	data	_
19-22	3868-3872	were	_
19-23	3873-3882	collected	_
19-24	3883-3885	at	_
19-25	3886-3889	the	_
19-26	3890-3900	University	_
19-27	3901-3903	of	_
19-28	3904-3916	Pennsylvania	_
19-29	3917-3923	Center	_
19-30	3924-3927	for	_
19-31	3928-3938	Functional	_
19-32	3939-3951	Neuroimaging	_
19-33	3952-3954	on	_
19-34	3955-3956	a	_
19-35	3957-3964	Siemens	_
19-36	3965-3966	3	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
19-37	3967-3972	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
19-38	3973-3977	Trio	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
19-39	3978-3988	whole-body	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
19-40	3989-3996	scanner	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
19-41	3997-3998	(	_
19-42	3999-4007	Erlangen	_
19-43	4008-4009	,	_
19-44	4010-4017	Germany	_
19-45	4018-4019	)	_
19-46	4020-4021	.	_

20-1	4022-4026	NUDs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
20-2	4027-4033	smoked	_
20-3	4034-4035	‘	_
20-4	4036-4038	as	_
20-5	4039-4044	usual	_
20-6	4045-4046	’	_
20-7	4047-4049	on	_
20-8	4050-4053	the	_
20-9	4054-4057	day	_
20-10	4058-4060	of	_
20-11	4061-4064	the	_
20-12	4065-4073	scanning	_
20-13	4074-4081	session	_
20-14	4082-4083	,	_
20-15	4084-4087	and	_
20-16	4088-4091	all	_
20-17	4092-4096	NUDs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
20-18	4097-4103	smoked	_
20-19	4104-4105	a	_
20-20	4106-4115	cigarette	_
20-21	4116-4118	to	_
20-22	4119-4126	satiety	_
20-23	4127-4140	approximately	_
20-24	4141-4143	25	_
20-25	4144-4151	minutes	_
20-26	4152-4157	prior	_
20-27	4158-4160	to	_
20-28	4161-4164	the	_
20-29	4165-4169	scan	_
20-30	4170-4177	session	_
20-31	4178-4179	.	_

21-1	4180-4192	Participants	_
21-2	4193-4197	were	_
21-3	4198-4204	placed	_
21-4	4205-4207	on	_
21-5	4208-4211	the	_
21-6	4212-4219	scanner	_
21-7	4220-4225	table	_
21-8	4226-4227	,	_
21-9	4228-4231	and	_
21-10	4232-4235	the	_
21-11	4236-4240	head	_
21-12	4241-4244	was	_
21-13	4245-4255	stabilized	_
21-14	4256-4262	within	_
21-15	4263-4266	the	_
21-16	4267-4271	head	_
21-17	4272-4276	coil	_
21-18	4277-4282	using	_
21-19	4283-4287	foam	_
21-20	4288-4290	to	_
21-21	4291-4299	minimize	_
21-22	4300-4304	head	_
21-23	4305-4311	motion	_
21-24	4312-4313	.	_

22-1	4314-4318	Scan	_
22-2	4319-4327	sessions	_
22-3	4328-4336	involved	_
22-4	4337-4338	a	_
22-5	4339-4348	10-second	_
22-6	4349-4358	localizer	_
22-7	4359-4363	scan	_
22-8	4364-4366	to	_
22-9	4367-4373	ensure	_
22-10	4374-4378	good	_
22-11	4379-4383	head	_
22-12	4384-4393	placement	_
22-13	4394-4397	and	_
22-14	4398-4403	slice	_
22-15	4404-4413	selection	_
22-16	4414-4422	covering	_
22-17	4423-4426	the	_
22-18	4427-4432	whole	_
22-19	4433-4438	brain	_
22-20	4439-4440	,	_
22-21	4441-4449	followed	_
22-22	4450-4452	by	_
22-23	4453-4454	a	_
22-24	4455-4470	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
22-25	4471-4482	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
22-26	4483-4500	three-dimensional	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
22-27	4501-4502	(	_
22-28	4503-4505	3D	_
22-29	4506-4507	)	_
22-30	4508-4521	magnetization	_
22-31	4522-4530	prepared	_
22-32	4531-4536	rapid	_
22-33	4537-4548	acquisition	_
22-34	4549-4557	gradient	_
22-35	4558-4562	echo	http://maven.renci.org/NeuroBridge/neurobridge#Age
22-36	4563-4564	(	http://maven.renci.org/NeuroBridge/neurobridge#Age
22-37	4565-4571	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#Age
22-38	4572-4573	)	http://maven.renci.org/NeuroBridge/neurobridge#Age
22-39	4574-4578	scan	_
22-40	4579-4580	(	_
22-41	4581-4586	field	_
22-42	4587-4589	of	_
22-43	4590-4594	view	_
22-44	4595-4596	(	_
22-45	4597-4600	FOV	_
22-46	4601-4602	)	_
22-47	4603-4609	=250mm	_
22-48	4610-4611	,	_
22-49	4612-4623	256×256×192	_
22-50	4624-4630	matrix	_
22-51	4631-4632	,	_
22-52	4633-4638	slice	_
22-53	4639-4650	thickness=1	_
22-54	4651-4653	mm	_
22-55	4654-4655	,	_
22-56	4656-4666	repetition	_
22-57	4667-4671	time	_
22-58	4672-4673	(	_
22-59	4674-4676	TR	_
22-60	4677-4678	)	_
22-61	4679-4686	=1620ms	_
22-62	4687-4688	,	_
22-63	4689-4693	echo	_
22-64	4694-4698	time	_
22-65	4699-4700	(	_
22-66	4701-4703	TE	_
22-67	4704-4705	)	_
22-68	4706-4710	=3ms	_
22-69	4711-4712	)	_
22-70	4713-4714	.	_

23-1	4715-4728	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
23-2	4729-4733	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
23-3	4734-4738	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
23-4	4739-4743	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
23-5	4744-4748	were	_
23-6	4749-4757	acquired	_
23-7	4758-4763	using	_
23-8	4764-4765	a	_
23-9	4766-4774	gradient	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
23-10	4775-4779	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
23-11	4780-4791	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
23-12	4792-4799	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
23-13	4800-4808	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
23-14	4809-4810	(	_
23-15	4811-4820	FOV=220mm	_
23-16	4821-4822	,	_
23-17	4823-4831	64×64×64	_
23-18	4832-4838	matrix	_
23-19	4839-4840	,	_
23-20	4841-4846	slice	_
23-21	4847-4860	thickness=4mm	_
23-22	4861-4862	,	_
23-23	4863-4868	TR=2s	_
23-24	4869-4870	,	_
23-25	4871-4878	TE=24ms	_
23-26	4879-4880	,	_
23-27	4881-4884	150	_
23-28	4885-4892	volumes	_
23-29	4893-4897	with	_
23-30	4898-4900	no	_
23-31	4901-4912	inter-slice	_
23-32	4913-4916	gap	_
23-33	4917-4918	)	_
23-34	4919-4920	.	_

24-1	4921-4933	Participants	_
24-2	4934-4938	were	_
24-3	4939-4949	instructed	_
24-4	4950-4952	to	_
24-5	4953-4956	lie	_
24-6	4957-4962	still	_
24-7	4963-4965	in	_
24-8	4966-4969	the	_
24-9	4970-4977	scanner	_
24-10	4978-4981	and	_
24-11	4982-4986	keep	_
24-12	4987-4992	their	_
24-13	4993-4997	eyes	_
24-14	4998-5002	open	_
24-15	5003-5004	.	_

25-1	5005-5007	An	_
25-2	5008-5018	eye-camera	_
25-3	5019-5026	outside	_
25-4	5027-5029	of	_
25-5	5030-5033	the	_
25-6	5034-5041	scanner	_
25-7	5042-5051	monitored	_
25-8	5052-5064	participants	_
25-9	5065-5066	’	_
25-10	5067-5071	eyes	_
25-11	5072-5074	to	_
25-12	5075-5081	ensure	_
25-13	5082-5086	that	_
25-14	5087-5091	they	_
25-15	5092-5100	remained	_
25-16	5101-5106	awake	_
25-17	5107-5113	during	_
25-18	5114-5117	the	_
25-19	5118-5122	scan	_
25-20	5123-5130	session	_
25-21	5131-5132	.	_

26-1	5133-5136	All	_
26-2	5137-5149	participants	_
26-3	5150-5158	remained	_
26-4	5159-5164	awake	_
26-5	5165-5175	throughout	_
26-6	5176-5179	the	_
26-7	5180-5184	scan	_
26-8	5185-5192	session	_
26-9	5193-5194	.	_

27-1	5195-5199	Data	_
27-2	5200-5208	Analysis	_
27-3	5209-5213	Each	_
27-4	5214-5225	participant	_
27-5	5226-5227	’	_
27-6	5228-5229	s	_
27-7	5230-5236	rsfMRI	_
27-8	5237-5241	data	_
27-9	5242-5246	were	_
27-10	5247-5260	pre-processed	_
27-11	5261-5266	using	_
27-12	5267-5278	Statistical	_
27-13	5279-5289	Parametric	_
27-14	5290-5297	Mapping	_
27-15	5298-5299	(	_
27-16	5300-5304	SPM8	_
27-17	5305-5306	,	_
27-18	5307-5315	Wellcome	_
27-19	5316-5326	Department	_
27-20	5327-5329	of	_
27-21	5330-5339	Cognitive	_
27-22	5340-5349	Neurology	_
27-23	5350-5351	,	_
27-24	5352-5358	London	_
27-25	5359-5360	,	_
27-26	5361-5363	UK	_
27-27	5364-5365	)	_
27-28	5366-5369	and	_
27-29	5370-5374	AFNI	_
27-30	5375-5376	(	_
27-31	5377-5382	https	_
27-32	5383-5384	:	_
27-33	5385-5405	//afni.nimh.nih.gov/	_
27-34	5406-5407	)	_
27-35	5408-5416	software	_
27-36	5417-5425	packages	_
27-37	5426-5427	.	_

28-1	5428-5440	Specifically	_
28-2	5441-5442	,	_
28-3	5443-5446	the	_
28-4	5447-5452	first	_
28-5	5453-5454	6	_
28-6	5455-5462	volumes	_
28-7	5463-5467	were	_
28-8	5468-5477	discarded	_
28-9	5478-5480	to	_
28-10	5481-5486	allow	_
28-11	5487-5500	magnetization	_
28-12	5501-5514	equilibration	_
28-13	5515-5516	.	_

29-1	5517-5527	De-spiking	_
29-2	5528-5531	was	_
29-3	5532-5539	applied	_
29-4	5540-5542	to	_
29-5	5543-5546	the	_
29-6	5547-5556	remaining	_
29-7	5557-5564	volumes	_
29-8	5565-5570	using	_
29-9	5571-5580	3dDespike	_
29-10	5581-5582	,	_
29-11	5583-5591	followed	_
29-12	5592-5594	by	_
29-13	5595-5605	slice-time	_
29-14	5606-5616	correction	_
29-15	5617-5622	using	_
29-16	5623-5631	3dTshift	_
29-17	5632-5633	.	_

30-1	5634-5637	For	_
30-2	5638-5642	head	_
30-3	5643-5649	motion	_
30-4	5650-5660	correction	_
30-5	5661-5662	,	_
30-6	5663-5666	the	_
30-7	5667-5673	rsfMRI	_
30-8	5674-5681	volumes	_
30-9	5682-5686	were	_
30-10	5687-5696	realigned	_
30-11	5697-5699	to	_
30-12	5700-5703	the	_
30-13	5704-5708	mean	_
30-14	5709-5715	volume	_
30-15	5716-5724	obtained	_
30-16	5725-5727	by	_
30-17	5728-5736	two-pass	_
30-18	5737-5746	averaging	_
30-19	5747-5752	using	_
30-20	5753-5761	3dvolreg	_
30-21	5762-5763	.	_

31-1	5764-5768	Head	_
31-2	5769-5775	motion	_
31-3	5776-5778	of	_
31-4	5779-5783	each	_
31-5	5784-5795	participant	_
31-6	5796-5797	’	_
31-7	5798-5799	s	_
31-8	5800-5806	rsfMRI	_
31-9	5807-5811	data	_
31-10	5812-5815	was	_
31-11	5816-5824	measured	_
31-12	5825-5827	by	_
31-13	5828-5832	root	_
31-14	5833-5837	mean	_
31-15	5838-5844	square	_
31-16	5845-5847	of	_
31-17	5848-5857	framewise	_
31-18	5858-5870	displacement	_
31-19	5871-5872	(	_
31-20	5873-5878	RMSFD	_
31-21	5879-5880	)	_
31-22	5881-5882	.	_

32-1	5883-5886	The	_
32-2	5887-5893	rsfMRI	_
32-3	5894-5898	data	_
32-4	5899-5901	of	_
32-5	5902-5906	each	_
32-6	5907-5914	subject	_
32-7	5915-5919	were	_
32-8	5920-5929	intensity	_
32-9	5930-5936	scaled	_
32-10	5937-5939	to	_
32-11	5940-5945	yield	_
32-12	5946-5947	a	_
32-13	5948-5953	whole	_
32-14	5954-5959	brain	_
32-15	5960-5964	mean	_
32-16	5965-5970	value	_
32-17	5971-5973	of	_
32-18	5974-5979	1,000	_
32-19	5980-5981	.	_

33-1	5982-5985	The	_
33-2	5986-5992	rsfMRI	_
33-3	5993-6000	signals	_
33-4	6001-6003	of	_
33-5	6004-6007	the	_
33-6	6008-6013	white	_
33-7	6014-6020	matter	_
33-8	6021-6024	and	_
33-9	6025-6038	cerebrospinal	_
33-10	6039-6044	fluid	_
33-11	6045-6046	,	_
33-12	6047-6049	as	_
33-13	6050-6054	well	_
33-14	6055-6057	as	_
33-15	6058-6059	6	_
33-16	6060-6065	rigid	_
33-17	6066-6070	head	_
33-18	6071-6077	motion	_
33-19	6078-6088	parameters	_
33-20	6089-6090	,	_
33-21	6091-6095	were	_
33-22	6096-6105	regressed	_
33-23	6106-6109	out	_
33-24	6110-6112	of	_
33-25	6113-6116	the	_
33-26	6117-6121	data	_
33-27	6122-6127	using	_
33-28	6128-6129	a	_
33-29	6130-6137	general	_
33-30	6138-6144	linear	_
33-31	6145-6150	model	_
33-32	6151-6152	.	_

34-1	6153-6161	Temporal	_
34-2	6162-6171	band-pass	_
34-3	6172-6181	filtering	_
34-4	6182-6183	(	_
34-5	6184-6188	0.01	_
34-6	6189-6190	<	_
34-7	6191-6192	f	_
34-8	6193-6194	<	_
34-9	6195-6199	0.08	_
34-10	6200-6202	Hz	_
34-11	6203-6204	)	_
34-12	6205-6208	was	_
34-13	6209-6213	then	_
34-14	6214-6223	performed	_
34-15	6224-6226	to	_
34-16	6227-6233	reduce	_
34-17	6234-6237	the	_
34-18	6238-6245	effects	_
34-19	6246-6248	of	_
34-20	6249-6262	low-frequency	_
34-21	6263-6268	drift	_
34-22	6269-6272	and	_
34-23	6273-6287	high-frequency	_
34-24	6288-6293	noise	_
34-25	6294-6295	.	_

35-1	6296-6303	Finally	_
35-2	6304-6305	,	_
35-3	6306-6310	SPM8	_
35-4	6311-6312	’	_
35-5	6313-6314	s	_
35-6	6315-6321	DARTEL	_
35-7	6322-6329	toolbox	_
35-8	6330-6333	was	_
35-9	6334-6338	used	_
35-10	6339-6341	to	_
35-11	6342-6351	spatially	_
35-12	6352-6361	normalize	_
35-13	6362-6372	individual	_
35-14	6373-6380	subject	_
35-15	6381-6387	images	_
35-16	6388-6390	to	_
35-17	6391-6392	a	_
35-18	6393-6398	group	_
35-19	6399-6407	template	_
35-20	6408-6411	and	_
35-21	6412-6416	then	_
35-22	6417-6427	normalized	_
35-23	6428-6430	to	_
35-24	6431-6434	the	_
35-25	6435-6443	Montreal	_
35-26	6444-6456	Neurological	_
35-27	6457-6466	Institute	_
35-28	6467-6468	(	_
35-29	6469-6472	MNI	_
35-30	6473-6474	)	_
35-31	6475-6480	space	_
35-32	6481-6485	with	_
35-33	6486-6488	an	_
35-34	6489-6495	affine	_
35-35	6496-6510	transformation	_
35-36	6511-6512	,	_
35-37	6513-6522	resampled	_
35-38	6523-6525	to	_
35-39	6526-6527	3	_
35-40	6528-6530	mm	_
35-41	6531-6532	×	_
35-42	6533-6534	3	_
35-43	6535-6537	mm	_
35-44	6538-6539	×	_
35-45	6540-6541	3	_
35-46	6542-6544	mm	_
35-47	6545-6551	voxels	_
35-48	6552-6553	,	_
35-49	6554-6557	and	_
35-50	6558-6566	smoothed	_
35-51	6567-6571	with	_
35-52	6572-6573	a	_
35-53	6574-6582	Gaussian	_
35-54	6583-6589	kernel	_
35-55	6590-6594	with	_
35-56	6595-6596	a	_
35-57	6597-6607	full-width	_
35-58	6608-6610	at	_
35-59	6611-6623	half-maximum	_
35-60	6624-6625	(	_
35-61	6626-6630	FWHM	_
35-62	6631-6632	)	_
35-63	6633-6635	of	_
35-64	6636-6637	6	_
35-65	6638-6640	mm	_
35-66	6641-6642	.	_

36-1	6643-6654	Statistical	_
36-2	6655-6663	Analysis	_
36-3	6664-6682	Independent-sample	_
36-4	6683-6690	t-tests	_
36-5	6691-6693	or	_
36-6	6694-6704	chi-square	_
36-7	6705-6710	tests	_
36-8	6711-6712	(	_
36-9	6713-6716	for	_
36-10	6717-6728	dichotomous	_
36-11	6729-6738	variables	_
36-12	6739-6740	)	_
36-13	6741-6749	compared	_
36-14	6750-6761	differences	_
36-15	6762-6769	between	_
36-16	6770-6776	groups	_
36-17	6777-6778	(	_
36-18	6779-6784	Table	_
36-19	6785-6786	1	_
36-20	6787-6788	)	_
36-21	6789-6790	.	_

37-1	6791-6798	Resting	_
37-2	6799-6804	state	_
37-3	6805-6812	network	_
37-4	6813-6824	computation	_
37-5	6825-6828	and	_
37-6	6829-6843	identification	_
37-7	6844-6849	Group	_
37-8	6850-6861	information	_
37-9	6862-6868	guided	_
37-10	6869-6880	independent	_
37-11	6881-6891	components	_
37-12	6892-6900	analysis	_
37-13	6901-6902	(	_
37-14	6903-6910	GIG-ICA	_
37-15	6911-6912	)	_
37-16	6913-6916	was	_
37-17	6917-6921	used	_
37-18	6922-6924	to	_
37-19	6925-6932	compute	_
37-20	6933-6940	subject	_
37-21	6941-6949	specific	_
37-22	6950-6957	resting	_
37-23	6958-6963	state	_
37-24	6964-6972	networks	_
37-25	6973-6974	,	_
37-26	6975-6978	and	_
37-27	6979-6986	resting	_
37-28	6987-6992	state	_
37-29	6993-7001	networks	_
37-30	7002-7004	at	_
37-31	7005-7006	a	_
37-32	7007-7012	group	_
37-33	7013-7018	level	_
37-34	7019-7023	were	_
37-35	7024-7028	used	_
37-36	7029-7031	as	_
37-37	7032-7042	references	_
37-38	7043-7045	to	_
37-39	7046-7053	achieve	_
37-40	7054-7070	inter-individual	_
37-41	7071-7084	comparability	_
37-42	7085-7087	of	_
37-43	7088-7091	the	_
37-44	7092-7099	subject	_
37-45	7100-7108	specific	_
37-46	7109-7116	resting	_
37-47	7117-7122	state	_
37-48	7123-7131	networks	_
37-49	7132-7133	.	_

38-1	7134-7146	Specifically	_
38-2	7147-7148	,	_
38-3	7149-7152	FSL	_
38-4	7153-7160	Melodic	_
38-5	7161-7162	,	_
38-6	7163-7167	with	_
38-7	7168-7171	its	_
38-8	7172-7179	default	_
38-9	7180-7187	setting	_
38-10	7188-7189	,	_
38-11	7190-7193	was	_
38-12	7194-7198	used	_
38-13	7199-7201	to	_
38-14	7202-7209	compute	_
38-15	7210-7221	independent	_
38-16	7222-7232	components	_
38-17	7233-7234	(	_
38-18	7235-7238	ICs	_
38-19	7239-7240	)	_
38-20	7241-7243	at	_
38-21	7244-7245	a	_
38-22	7246-7251	group	_
38-23	7252-7257	level	_
38-24	7258-7262	with	_
38-25	7263-7266	the	_
38-26	7267-7273	number	_
38-27	7274-7276	of	_
38-28	7277-7280	ICs	_
38-29	7281-7294	automatically	_
38-30	7295-7304	estimated	_
38-31	7305-7310	using	_
38-32	7311-7317	Akaike	_
38-33	7318-7329	Information	_
38-34	7330-7339	Criterion	_
38-35	7340-7341	.	_

39-1	7342-7345	The	_
39-2	7346-7352	number	_
39-3	7353-7355	of	_
39-4	7356-7366	components	_
39-5	7367-7370	was	_
39-6	7371-7373	10	_
39-7	7374-7375	,	_
39-8	7376-7379	and	_
39-9	7380-7385	these	_
39-10	7386-7391	group	_
39-11	7392-7397	level	_
39-12	7398-7401	ICs	_
39-13	7402-7406	were	_
39-14	7407-7411	then	_
39-15	7412-7416	used	_
39-16	7417-7419	as	_
39-17	7420-7428	guidance	_
39-18	7429-7440	information	_
39-19	7441-7443	to	_
39-20	7444-7451	compute	_
39-21	7452-7459	subject	_
39-22	7460-7468	specific	_
39-23	7469-7472	ICs	_
39-24	7473-7476	and	_
39-25	7477-7482	their	_
39-26	7483-7493	associated	_
39-27	7494-7498	time	_
39-28	7499-7506	courses	_
39-29	7507-7512	using	_
39-30	7513-7516	the	_
39-31	7517-7524	GIG-ICA	_
39-32	7525-7526	.	_

40-1	7527-7530	The	_
40-2	7531-7534	ICs	_
40-3	7535-7538	are	_
40-4	7539-7547	referred	_
40-5	7548-7550	to	_
40-6	7551-7553	as	_
40-7	7554-7561	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
40-8	7562-7567	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
40-9	7568-7578	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
40-10	7579-7587	networks	_
40-11	7588-7589	(	_
40-12	7590-7594	RSNs	_
40-13	7595-7596	)	_
40-14	7597-7606	hereafter	_
40-15	7607-7608	.	_

41-1	7609-7611	To	_
41-2	7612-7620	identify	_
41-3	7621-7625	RSNs	_
41-4	7626-7633	altered	_
41-5	7634-7636	by	_
41-6	7637-7640	NUD	_
41-7	7641-7642	,	_
41-8	7643-7645	we	_
41-9	7646-7653	adopted	_
41-10	7654-7655	a	_
41-11	7656-7665	Grassmann	_
41-12	7666-7674	manifold	_
41-13	7675-7683	learning	_
41-14	7684-7690	method	_
41-15	7691-7693	to	_
41-16	7694-7699	build	_
41-17	7700-7714	classification	_
41-18	7715-7721	models	_
41-19	7722-7727	based	_
41-20	7728-7730	on	_
41-21	7731-7735	RSNs	_
41-22	7736-7740	that	_
41-23	7741-7745	were	_
41-24	7746-7754	selected	_
41-25	7755-7757	to	_
41-26	7758-7766	optimize	_
41-27	7767-7770	the	_
41-28	7771-7785	classification	_
41-29	7786-7797	performance	_
41-30	7798-7801	for	_
41-31	7802-7816	distinguishing	_
41-32	7817-7820	NUD	_
41-33	7821-7829	subjects	_
41-34	7830-7834	from	_
41-35	7835-7843	controls	_
41-36	7844-7846	by	_
41-37	7847-7850	the	_
41-38	7851-7858	pattern	_
41-39	7859-7873	classification	_
41-40	7874-7883	algorithm	_
41-41	7884-7885	.	_

42-1	7886-7892	Rather	_
42-2	7893-7897	than	_
42-3	7898-7907	analyzing	_
42-4	7908-7912	each	_
42-5	7913-7916	RSN	_
42-6	7917-7924	encoded	_
42-7	7925-7927	by	_
42-8	7928-7929	a	_
42-9	7930-7937	spatial	_
42-10	7938-7949	independent	_
42-11	7950-7959	component	_
42-12	7960-7970	separately	_
42-13	7971-7972	,	_
42-14	7973-7976	the	_
42-15	7977-7979	10	_
42-16	7980-7984	RSNs	_
42-17	7985-7989	from	_
42-18	7990-7994	each	_
42-19	7995-8005	individual	_
42-20	8006-8010	were	_
42-21	8011-8015	used	_
42-22	8016-8018	as	_
42-23	8019-8024	bases	_
42-24	8025-8028	for	_
42-25	8029-8030	a	_
42-26	8031-8037	linear	_
42-27	8038-8046	subspace	_
42-28	8047-8048	.	_

43-1	8049-8059	Similarity	_
43-2	8060-8068	measures	_
43-3	8069-8076	between	_
43-4	8077-8085	subjects	_
43-5	8086-8090	RSNs	_
43-6	8091-8095	were	_
43-7	8096-8104	computed	_
43-8	8105-8107	on	_
43-9	8108-8111	the	_
43-10	8112-8121	Grassmann	_
43-11	8122-8130	manifold	_
43-12	8131-8133	by	_
43-13	8134-8142	adopting	_
43-14	8143-8144	a	_
43-15	8145-8154	principal	_
43-16	8155-8160	angle	_
43-17	8161-8166	based	_
43-18	8167-8177	Riemannian	_
43-19	8178-8186	distance	_
43-20	8187-8188	.	_

44-1	8189-8194	These	_
44-2	8195-8205	similarity	_
44-3	8206-8214	measures	_
44-4	8215-8219	were	_
44-5	8220-8224	used	_
44-6	8225-8227	in	_
44-7	8228-8231	the	_
44-8	8232-8239	support	_
44-9	8240-8246	vector	_
44-10	8247-8254	machine	_
44-11	8255-8256	(	_
44-12	8257-8260	SVM	_
44-13	8261-8262	)	_
44-14	8263-8277	classification	_
44-15	8278-8279	.	_

45-1	8280-8282	In	_
45-2	8283-8294	conjunction	_
45-3	8295-8299	with	_
45-4	8300-8301	a	_
45-5	8302-8309	support	_
45-6	8310-8316	vector	_
45-7	8317-8324	machine	_
45-8	8325-8326	(	_
45-9	8327-8330	SVM	_
45-10	8331-8332	)	_
45-11	8333-8343	classifier	_
45-12	8344-8345	,	_
45-13	8346-8347	a	_
45-14	8348-8355	forward	_
45-15	8356-8365	component	_
45-16	8366-8375	selection	_
45-17	8376-8385	technique	_
45-18	8386-8389	was	_
45-19	8390-8397	adopted	_
45-20	8398-8400	to	_
45-21	8401-8407	select	_
45-22	8408-8412	RSNs	_
45-23	8413-8416	for	_
45-24	8417-8429	constructing	_
45-25	8430-8433	the	_
45-26	8434-8438	most	_
45-27	8439-8453	discriminative	_
45-28	8454-8457	set	_
45-29	8458-8460	of	_
45-30	8461-8465	RSNs	_
45-31	8466-8467	.	_

46-1	8468-8470	To	_
46-2	8471-8477	select	_
46-3	8478-8481	the	_
46-4	8482-8486	most	_
46-5	8487-8501	discriminative	_
46-6	8502-8512	components	_
46-7	8513-8514	,	_
46-8	8515-8518	the	_
46-9	8519-8526	forward	_
46-10	8527-8536	component	_
46-11	8537-8546	selection	_
46-12	8547-8556	algorithm	_
46-13	8557-8562	first	_
46-14	8563-8568	built	_
46-15	8569-8570	a	_
46-16	8571-8581	classifier	_
46-17	8582-8586	upon	_
46-18	8587-8591	each	_
46-19	8592-8602	individual	_
46-20	8603-8606	RSN	_
46-21	8607-8608	,	_
46-22	8609-8612	the	_
46-23	8613-8623	classifier	_
46-24	8624-8625	’	_
46-25	8626-8627	s	_
46-26	8628-8639	performance	_
46-27	8640-8643	was	_
46-28	8644-8648	then	_
46-29	8649-8658	estimated	_
46-30	8659-8663	with	_
46-31	8664-8665	a	_
46-32	8666-8674	ten-fold	_
46-33	8675-8691	cross-validation	_
46-34	8692-8694	so	_
46-35	8695-8699	that	_
46-36	8700-8704	each	_
46-37	8705-8708	RSN	_
46-38	8709-8714	could	_
46-39	8715-8717	be	_
46-40	8718-8727	evaluated	_
46-41	8728-8731	for	_
46-42	8732-8735	its	_
46-43	8736-8750	classification	_
46-44	8751-8762	performance	_
46-45	8763-8764	,	_
46-46	8765-8768	and	_
46-47	8769-8776	finally	_
46-48	8777-8780	the	_
46-49	8781-8790	component	_
46-50	8791-8795	with	_
46-51	8796-8799	the	_
46-52	8800-8804	best	_
46-53	8805-8819	classification	_
46-54	8820-8831	performance	_
46-55	8832-8835	was	_
46-56	8836-8844	selected	_
46-57	8845-8847	to	_
46-58	8848-8850	be	_
46-59	8851-8859	included	_
46-60	8860-8862	in	_
46-61	8863-8866	the	_
46-62	8867-8881	classification	_
46-63	8882-8883	.	_

47-1	8884-8886	By	_
47-2	8887-8896	combining	_
47-3	8897-8900	the	_
47-4	8901-8906	first	_
47-5	8907-8915	selected	_
47-6	8916-8925	component	_
47-7	8926-8929	and	_
47-8	8930-8933	one	_
47-9	8934-8936	of	_
47-10	8937-8940	the	_
47-11	8941-8946	other	_
47-12	8947-8957	components	_
47-13	8958-8959	,	_
47-14	8960-8961	a	_
47-15	8962-8972	classifier	_
47-16	8973-8978	could	_
47-17	8979-8981	be	_
47-18	8982-8987	built	_
47-19	8988-8992	upon	_
47-20	8993-8994	2	_
47-21	8995-9005	components	_
47-22	9006-9007	.	_

48-1	9008-9011	All	_
48-2	9012-9023	classifiers	_
48-3	9024-9029	built	_
48-4	9030-9034	upon	_
48-5	9035-9036	2	_
48-6	9037-9047	components	_
48-7	9048-9052	were	_
48-8	9053-9057	then	_
48-9	9058-9067	evaluated	_
48-10	9068-9073	using	_
48-11	9074-9077	the	_
48-12	9078-9082	same	_
48-13	9083-9099	cross-validation	_
48-14	9100-9101	,	_
48-15	9102-9105	and	_
48-16	9106-9109	the	_
48-17	9110-9120	components	_
48-18	9121-9125	with	_
48-19	9126-9129	the	_
48-20	9130-9134	best	_
48-21	9135-9149	classification	_
48-22	9150-9161	performance	_
48-23	9162-9166	were	_
48-24	9167-9175	selected	_
48-25	9176-9178	to	_
48-26	9179-9181	be	_
48-27	9182-9190	included	_
48-28	9191-9193	in	_
48-29	9194-9197	the	_
48-30	9198-9212	classification	_
48-31	9213-9214	.	_

49-1	9215-9219	This	_
49-2	9220-9229	procedure	_
49-3	9230-9233	was	_
49-4	9234-9242	repeated	_
49-5	9243-9245	to	_
49-6	9246-9253	include	_
49-7	9254-9258	more	_
49-8	9259-9269	components	_
49-9	9270-9272	in	_
49-10	9273-9276	the	_
49-11	9277-9291	classification	_
49-12	9292-9295	one	_
49-13	9296-9298	by	_
49-14	9299-9302	one	_
49-15	9303-9308	until	_
49-16	9309-9312	one	_
49-17	9313-9319	single	_
49-18	9320-9330	classifier	_
49-19	9331-9334	was	_
49-20	9335-9340	built	_
49-21	9341-9345	upon	_
49-22	9346-9349	all	_
49-23	9350-9359	available	_
49-24	9360-9370	components	_
49-25	9371-9374	and	_
49-26	9375-9376	a	_
49-27	9377-9385	function	_
49-28	9386-9388	of	_
49-29	9389-9403	classification	_
49-30	9404-9415	performance	_
49-31	9416-9418	of	_
49-32	9419-9428	different	_
49-33	9429-9436	numbers	_
49-34	9437-9439	of	_
49-35	9440-9450	components	_
49-36	9451-9454	was	_
49-37	9455-9463	obtained	_
49-38	9464-9465	.	_

50-1	9466-9473	Finally	_
50-2	9474-9475	,	_
50-3	9476-9482	across	_
50-4	9483-9486	all	_
50-5	9487-9490	the	_
50-6	9491-9495	best	_
50-7	9496-9507	classifiers	_
50-8	9508-9512	with	_
50-9	9513-9522	different	_
50-10	9523-9530	numbers	_
50-11	9531-9533	of	_
50-12	9534-9544	components	_
50-13	9545-9546	,	_
50-14	9547-9550	the	_
50-15	9551-9562	combination	_
50-16	9563-9565	of	_
50-17	9566-9576	components	_
50-18	9577-9581	with	_
50-19	9582-9585	the	_
50-20	9586-9593	overall	_
50-21	9594-9598	best	_
50-22	9599-9613	classification	_
50-23	9614-9625	performance	_
50-24	9626-9629	was	_
50-25	9630-9640	identified	_
50-26	9641-9643	to	_
50-27	9644-9646	be	_
50-28	9647-9655	included	_
50-29	9656-9658	in	_
50-30	9659-9662	the	_
50-31	9663-9668	final	_
50-32	9669-9683	classification	_
50-33	9684-9685	.	_

51-1	9686-9689	The	_
51-2	9690-9699	component	_
51-3	9700-9709	selection	_
51-4	9710-9713	and	_
51-5	9714-9717	the	_
51-6	9718-9728	classifier	_
51-7	9729-9741	construction	_
51-8	9742-9746	were	_
51-9	9747-9754	carried	_
51-10	9755-9758	out	_
51-11	9759-9764	based	_
51-12	9765-9767	on	_
51-13	9768-9772	only	_
51-14	9773-9781	training	_
51-15	9782-9786	data	_
51-16	9787-9788	.	_

52-1	9789-9801	Specifically	_
52-2	9802-9803	,	_
52-3	9804-9806	we	_
52-4	9807-9811	used	_
52-5	9812-9813	a	_
52-6	9814-9821	10-fold	_
52-7	9822-9838	cross-validation	_
52-8	9839-9847	strategy	_
52-9	9848-9850	to	_
52-10	9851-9856	build	_
52-11	9857-9868	classifiers	_
52-12	9869-9872	and	_
52-13	9873-9881	evaluate	_
52-14	9882-9887	their	_
52-15	9888-9899	performance	_
52-16	9900-9901	.	_

53-1	9902-9905	The	_
53-2	9906-9922	cross-validation	_
53-3	9923-9932	procedure	_
53-4	9933-9940	carried	_
53-5	9941-9944	out	_
53-6	9945-9946	a	_
53-7	9947-9952	total	_
53-8	9953-9955	of	_
53-9	9956-9958	10	_
53-10	9959-9967	training	_
53-11	9968-9971	and	_
53-12	9972-9979	testing	_
53-13	9980-9984	runs	_
53-14	9985-9986	.	_

54-1	9987-9989	In	_
54-2	9990-9994	each	_
54-3	9995-9998	run	_
54-4	9999-10000	,	_
54-5	10001-10004	one	_
54-6	10005-10010	tenth	_
54-7	10011-10013	of	_
54-8	10014-10017	the	_
54-9	10018-10026	subjects	_
54-10	10027-10031	were	_
54-11	10032-10040	selected	_
54-12	10041-10043	as	_
54-13	10044-10047	the	_
54-14	10048-10055	testing	_
54-15	10056-10062	sample	_
54-16	10063-10064	,	_
54-17	10065-10068	and	_
54-18	10069-10070	a	_
54-19	10071-10081	classifier	_
54-20	10082-10085	was	_
54-21	10086-10091	built	_
54-22	10092-10096	upon	_
54-23	10097-10101	data	_
54-24	10102-10104	of	_
54-25	10105-10108	all	_
54-26	10109-10118	remaining	_
54-27	10119-10127	subjects	_
54-28	10128-10131	and	_
54-29	10132-10138	tested	_
54-30	10139-10144	based	_
54-31	10145-10147	on	_
54-32	10148-10151	the	_
54-33	10152-10160	left-out	_
54-34	10161-10168	testing	_
54-35	10169-10176	subject	_
54-36	10177-10178	.	_

55-1	10179-10182	The	_
55-2	10183-10191	training	_
55-3	10192-10195	and	_
55-4	10196-10203	testing	_
55-5	10204-10207	run	_
55-6	10208-10211	was	_
55-7	10212-10220	repeated	_
55-8	10221-10226	until	_
55-9	10227-10230	all	_
55-10	10231-10239	subjects	_
55-11	10240-10243	had	_
55-12	10244-10248	been	_
55-13	10249-10257	selected	_
55-14	10258-10260	as	_
55-15	10261-10268	testing	_
55-16	10269-10276	samples	_
55-17	10277-10278	.	_

56-1	10279-10286	Finally	_
56-2	10287-10288	,	_
56-3	10289-10292	the	_
56-4	10293-10300	overall	_
56-5	10301-10315	classification	_
56-6	10316-10327	performance	_
56-7	10328-10331	was	_
56-8	10332-10341	evaluated	_
56-9	10342-10347	based	_
56-10	10348-10350	on	_
56-11	10351-10354	the	_
56-12	10355-10357	10	_
56-13	10358-10366	training	_
56-14	10367-10370	and	_
56-15	10371-10378	testing	_
56-16	10379-10383	runs	_
56-17	10384-10385	.	_

57-1	10386-10388	In	_
57-2	10389-10393	each	_
57-3	10394-10402	training	_
57-4	10403-10406	and	_
57-5	10407-10414	testing	_
57-6	10415-10418	run	_
57-7	10419-10420	,	_
57-8	10421-10422	a	_
57-9	10423-10433	classifier	_
57-10	10434-10438	with	_
57-11	10439-10442	the	_
57-12	10443-10447	best	_
57-13	10448-10462	discriminative	_
57-14	10463-10474	performance	_
57-15	10475-10480	given	_
57-16	10481-10484	the	_
57-17	10485-10493	training	_
57-18	10494-10501	dataset	_
57-19	10502-10505	was	_
57-20	10506-10516	identified	_
57-21	10517-10518	.	_

58-1	10519-10523	That	_
58-2	10524-10526	is	_
58-3	10527-10528	,	_
58-4	10529-10532	for	_
58-5	10533-10537	RSNs	_
58-6	10538-10540	of	_
58-7	10541-10544	the	_
58-8	10545-10553	training	_
58-9	10554-10562	subjects	_
58-10	10563-10564	,	_
58-11	10565-10567	we	_
58-12	10568-10572	used	_
58-13	10573-10574	a	_
58-14	10575-10581	nested	_
58-15	10582-10589	10-fold	_
58-16	10590-10606	cross-validation	_
58-17	10607-10616	procedure	_
58-18	10617-10619	to	_
58-19	10620-10626	select	_
58-20	10627-10630	the	_
58-21	10631-10635	best	_
58-22	10636-10639	set	_
58-23	10640-10642	of	_
58-24	10643-10647	RSNs	_
58-25	10648-10651	and	_
58-26	10652-10657	build	_
58-27	10658-10659	a	_
58-28	10660-10663	SVM	_
58-29	10664-10674	classifier	_
58-30	10675-10677	by	_
58-31	10678-10684	tuning	_
58-32	10685-10688	its	_
58-33	10689-10699	parameters	_
58-34	10700-10702	to	_
58-35	10703-10710	achieve	_
58-36	10711-10714	the	_
58-37	10715-10719	best	_
58-38	10720-10734	classification	_
58-39	10735-10739	rate	_
58-40	10740-10741	.	_

59-1	10742-10748	Within	_
59-2	10749-10753	each	_
59-3	10754-10757	run	_
59-4	10758-10760	of	_
59-5	10761-10764	the	_
59-6	10765-10781	cross-validation	_
59-7	10782-10783	,	_
59-8	10784-10791	another	_
59-9	10792-10799	10-fold	_
59-10	10800-10816	cross-validation	_
59-11	10817-10820	was	_
59-12	10821-10830	performed	_
59-13	10831-10833	to	_
59-14	10834-10840	select	_
59-15	10841-10845	RSNs	_
59-16	10846-10849	and	_
59-17	10850-10858	optimize	_
59-18	10859-10862	the	_
59-19	10863-10877	classification	_
59-20	10878-10888	parameters	_
59-21	10889-10894	based	_
59-22	10895-10897	on	_
59-23	10898-10901	the	_
59-24	10902-10910	training	_
59-25	10911-10915	data	_
59-26	10916-10917	.	_

60-1	10918-10922	With	_
60-2	10923-10927	this	_
60-3	10928-10934	nested	_
60-4	10935-10942	10-fold	_
60-5	10943-10959	cross-validation	_
60-6	10960-10968	strategy	_
60-7	10969-10970	,	_
60-8	10971-10973	we	_
60-9	10974-10979	built	_
60-10	10980-10991	classifiers	_
60-11	10992-10995	and	_
60-12	10996-11005	estimated	_
60-13	11006-11009	the	_
60-14	11010-11021	statistical	_
60-15	11022-11034	significance	_
60-16	11035-11037	of	_
60-17	11038-11041	our	_
60-18	11042-11056	classification	_
60-19	11057-11064	results	_
60-20	11065-11070	using	_
60-21	11071-11075	10e5	_
60-22	11076-11087	permutation	_
60-23	11088-11093	tests	_
60-24	11094-11096	by	_
60-25	11097-11105	building	_
60-26	11106-11117	classifiers	_
60-27	11118-11120	on	_
60-28	11121-11125	data	_
60-29	11126-11130	with	_
60-30	11131-11139	randomly	_
60-31	11140-11148	assigned	_
60-32	11149-11154	class	_
60-33	11155-11161	labels	_
60-34	11162-11163	.	_

61-1	11164-11166	In	_
61-2	11167-11175	addition	_
61-3	11176-11178	to	_
61-4	11179-11193	classification	_
61-5	11194-11202	accuracy	_
61-6	11203-11204	,	_
61-7	11205-11213	receiver	_
61-8	11214-11223	operating	_
61-9	11224-11238	characteristic	_
61-10	11239-11245	curves	_
61-11	11246-11247	(	_
61-12	11248-11252	ROCs	_
61-13	11253-11254	)	_
61-14	11255-11258	and	_
61-15	11259-11262	the	_
61-16	11263-11267	area	_
61-17	11268-11273	under	_
61-18	11274-11276	an	_
61-19	11277-11280	ROC	_
61-20	11281-11286	curve	_
61-21	11287-11288	(	_
61-22	11289-11294	AUROC	_
61-23	11295-11296	)	_
61-24	11297-11301	were	_
61-25	11302-11306	also	_
61-26	11307-11315	computed	_
61-27	11316-11321	based	_
61-28	11322-11324	on	_
61-29	11325-11328	the	_
61-30	11329-11343	classification	_
61-31	11344-11350	scores	_
61-32	11351-11353	of	_
61-33	11354-11361	testing	_
61-34	11362-11370	subjects	_
61-35	11371-11372	.	_

62-1	11373-11375	An	_
62-2	11376-11379	ROC	_
62-3	11380-11385	curve	_
62-4	11386-11394	provides	_
62-5	11395-11408	visualization	_
62-6	11409-11411	of	_
62-7	11412-11423	sensitivity	_
62-8	11424-11427	and	_
62-9	11428-11439	specificity	_
62-10	11440-11442	of	_
62-11	11443-11444	a	_
62-12	11445-11455	classifier	_
62-13	11456-11458	at	_
62-14	11459-11468	different	_
62-15	11469-11483	classification	_
62-16	11484-11494	thresholds	_
62-17	11495-11496	;	_
62-18	11497-11504	whereas	_
62-19	11505-11506	,	_
62-20	11507-11509	an	_
62-21	11510-11515	AUROC	_
62-22	11516-11524	provides	_
62-23	11525-11526	a	_
62-24	11527-11534	summary	_
62-25	11535-11541	number	_
62-26	11542-11544	of	_
62-27	11545-11547	an	_
62-28	11548-11551	ROC	_
62-29	11552-11557	curve	_
62-30	11558-11559	.	_

63-1	11560-11561	A	_
63-2	11562-11568	larger	_
63-3	11569-11574	AUROC	_
63-4	11575-11584	indicates	_
63-5	11585-11586	a	_
63-6	11587-11593	better	_
63-7	11594-11608	classification	_
63-8	11609-11620	performance	_
63-9	11621-11622	.	_

64-1	11623-11626	Due	_
64-2	11627-11629	to	_
64-3	11630-11643	inter-subject	_
64-4	11644-11655	variability	_
64-5	11656-11657	,	_
64-6	11658-11661	the	_
64-7	11662-11666	best	_
64-8	11667-11670	set	_
64-9	11671-11673	of	_
64-10	11674-11678	RSNs	_
64-11	11679-11682	for	_
64-12	11683-11698	differentiating	_
64-13	11699-11707	patients	_
64-14	11708-11712	from	_
64-15	11713-11715	HC	_
64-16	11716-11724	subjects	_
64-17	11725-11731	varied	_
64-18	11732-11738	across	_
64-19	11739-11747	training	_
64-20	11748-11751	and	_
64-21	11752-11759	testing	_
64-22	11760-11764	runs	_
64-23	11765-11766	.	_

65-1	11767-11776	Therefore	_
65-2	11777-11778	,	_
65-3	11779-11781	we	_
65-4	11782-11790	computed	_
65-5	11791-11794	the	_
65-6	11795-11804	frequency	_
65-7	11805-11807	of	_
65-8	11808-11812	RSNs	_
65-9	11813-11821	selected	_
65-10	11822-11826	into	_
65-11	11827-11830	the	_
65-12	11831-11835	best	_
65-13	11836-11839	set	_
65-14	11840-11842	of	_
65-15	11843-11857	discriminative	_
65-16	11858-11862	RSNs	_
65-17	11863-11865	in	_
65-18	11866-11869	all	_
65-19	11870-11874	runs	_
65-20	11875-11876	.	_

66-1	11877-11880	The	_
66-2	11881-11885	most	_
66-3	11886-11896	frequently	_
66-4	11897-11905	selected	_
66-5	11906-11910	RSNs	_
66-6	11911-11914	are	_
66-7	11915-11918	the	_
66-8	11919-11923	most	_
66-9	11924-11933	different	_
66-10	11934-11938	RSNs	_
66-11	11939-11946	between	_
66-12	11947-11951	NUDs	_
66-13	11952-11955	and	_
66-14	11956-11967	non-smoking	_
66-15	11968-11976	controls	_
66-16	11977-11978	.	_

67-1	11979-11980	A	_
67-2	11981-11990	flowchart	_
67-3	11991-11993	of	_
67-4	11994-11997	the	_
67-5	11998-12004	nested	_
67-6	12005-12012	10-fold	_
67-7	12013-12029	cross-validation	_
67-8	12030-12032	is	_
67-9	12033-12038	shown	_
67-10	12039-12041	in	_
67-11	12042-12048	Figure	_
67-12	12049-12050	1	_
67-13	12051-12052	.	_

68-1	12053-12056	The	_
68-2	12057-12063	nested	_
68-3	12064-12071	10-fold	_
68-4	12072-12088	cross-validation	_
68-5	12089-12103	classification	_
68-6	12104-12114	experiment	_
68-7	12115-12118	was	_
68-8	12119-12127	repeated	_
68-9	12128-12130	10	_
68-10	12131-12136	times	_
68-11	12137-12141	with	_
68-12	12142-12148	random	_
68-13	12149-12155	splits	_
68-14	12156-12158	of	_
68-15	12159-12167	training	_
68-16	12168-12171	and	_
68-17	12172-12179	testing	_
68-18	12180-12188	subjects	_
68-19	12189-12192	for	_
68-20	12193-12202	obtaining	_
68-21	12203-12204	a	_
68-22	12205-12211	robust	_
68-23	12212-12222	estimation	_
68-24	12223-12225	of	_
68-25	12226-12229	the	_
68-26	12230-12244	classification	_
68-27	12245-12256	performance	_
68-28	12257-12258	.	_

69-1	12259-12272	Visualization	_
69-2	12273-12275	of	_
69-3	12276-12279	the	_
69-4	12280-12293	heterogeneity	_
69-5	12294-12296	of	_
69-6	12297-12300	NUD	_
69-7	12301-12303	in	_
69-8	12304-12314	individual	_
69-9	12315-12322	smokers	_
69-10	12323-12324	A	_
69-11	12325-12334	Grassmann	_
69-12	12335-12343	manifold	_
69-13	12344-12352	distance	_
69-14	12353-12359	metric	_
69-15	12360-12368	measured	_
69-16	12369-12379	similarity	_
69-17	12380-12387	between	_
69-18	12388-12400	participants	_
69-19	12401-12406	based	_
69-20	12407-12409	on	_
69-21	12410-12415	their	_
69-22	12416-12420	RSNs	_
69-23	12421-12425	that	_
69-24	12426-12429	are	_
69-25	12430-12434	most	_
69-26	12435-12444	different	_
69-27	12445-12452	between	_
69-28	12453-12457	NUDs	_
69-29	12458-12461	and	_
69-30	12462-12473	non-smoking	_
69-31	12474-12482	controls	_
69-32	12483-12484	.	_

70-1	12485-12497	Specifically	_
70-2	12498-12499	,	_
70-3	12500-12508	distance	_
70-4	12509-12511	to	_
70-5	12512-12516	each	_
70-6	12517-12524	control	_
70-7	12525-12528	was	_
70-8	12529-12539	calculated	_
70-9	12540-12543	and	_
70-10	12544-12548	then	_
70-11	12549-12557	averaged	_
70-12	12558-12561	for	_
70-13	12562-12563	a	_
70-14	12564-12570	smoker	_
70-15	12571-12573	or	_
70-16	12574-12575	a	_
70-17	12576-12583	control	_
70-18	12584-12591	subject	_
70-19	12592-12593	.	_

71-1	12594-12597	The	_
71-2	12598-12606	distance	_
71-3	12607-12614	between	_
71-4	12615-12618	the	_
71-5	12619-12623	same	_
71-6	12624-12632	subjects	_
71-7	12633-12636	was	_
71-8	12637-12641	zero	_
71-9	12642-12643	,	_
71-10	12644-12654	indicating	_
71-11	12655-12659	that	_
71-12	12660-12663	our	_
71-13	12664-12672	manifold	_
71-14	12673-12681	distance	_
71-15	12682-12688	metric	_
71-16	12689-12698	satisfies	_
71-17	12699-12700	“	_
71-18	12701-12709	identity	_
71-19	12710-12712	of	_
71-20	12713-12727	indiscernibles	_
71-21	12728-12729	”	_
71-22	12730-12731	.	_

72-1	12732-12748	Multidimensional	_
72-2	12749-12756	scaling	_
72-3	12757-12758	(	_
72-4	12759-12762	MDS	_
72-5	12763-12764	)	_
72-6	12765-12768	was	_
72-7	12769-12776	adopted	_
72-8	12777-12779	to	_
72-9	12780-12789	visualize	_
72-10	12790-12793	the	_
72-11	12794-12799	level	_
72-12	12800-12802	of	_
72-13	12803-12813	similarity	_
72-14	12814-12816	of	_
72-15	12817-12827	individual	_
72-16	12828-12836	subjects	_
72-17	12837-12839	in	_
72-18	12840-12842	2D	_
72-19	12843-12848	space	_
72-20	12849-12850	(	_
72-21	12851-12858	mdscale	_
72-22	12859-12860	,	_
72-23	12861-12867	MATLAB	_
72-24	12868-12873	2014a	_
72-25	12874-12875	)	_
72-26	12876-12877	.	_

73-1	12878-12883	Based	_
73-2	12884-12886	on	_
73-3	12887-12890	the	_
73-4	12891-12901	similarity	_
73-5	12902-12909	measure	_
73-6	12910-12911	,	_
73-7	12912-12913	,	_
73-8	12914-12921	between	_
73-9	12922-12925	two	_
73-10	12926-12938	participants	_
73-11	12939-12947	computed	_
73-12	12948-12953	using	_
73-13	12954-12957	the	_
73-14	12958-12967	Grassmann	_
73-15	12968-12976	manifold	_
73-16	12977-12985	distance	_
73-17	12986-12992	metric	_
73-18	12993-12994	,	_
73-19	12995-13005	functional	_
73-20	13006-13014	distance	_
73-21	13015-13022	between	_
73-22	13023-13027	them	_
73-23	13028-13031	was	_
73-24	13032-13038	simple	_
73-25	13039-13049	calculated	_
73-26	13050-13052	as	_
73-27	13053-13054	.	_

74-1	13055-13058	The	_
74-2	13059-13066	average	_
74-3	13067-13077	functional	_
74-4	13078-13086	distance	_
74-5	13087-13094	between	_
74-6	13095-13103	controls	_
74-7	13104-13107	and	_
74-8	13108-13112	each	_
74-9	13113-13123	individual	_
74-10	13124-13135	participant	_
74-11	13136-13144	measured	_
74-12	13145-13148	the	_
74-13	13149-13159	difference	_
74-14	13160-13167	between	_
74-15	13168-13179	individuals	_
74-16	13180-13184	with	_
74-17	13185-13188	NUD	_
74-18	13189-13192	and	_
74-19	13193-13201	controls	_
74-20	13202-13203	.	_

75-1	13204-13213	Voxelwise	_
75-2	13214-13216	FC	_
75-3	13217-13225	measures	_
75-4	13226-13228	of	_
75-5	13229-13239	individual	_
75-6	13240-13244	RSNs	_
75-7	13245-13249	Each	_
75-8	13250-13259	voxelwise	_
75-9	13260-13262	FC	_
75-10	13263-13270	measure	_
75-11	13271-13273	of	_
75-12	13274-13277	one	_
75-13	13278-13281	RSN	_
75-14	13282-13285	was	_
75-15	13286-13294	computed	_
75-16	13295-13297	as	_
75-17	13298-13305	Pearson	_
75-18	13306-13317	correlation	_
75-19	13318-13330	coefficients	_
75-20	13331-13338	between	_
75-21	13339-13342	the	_
75-22	13343-13347	time	_
75-23	13348-13354	course	_
75-24	13355-13357	of	_
75-25	13358-13361	the	_
75-26	13362-13367	voxel	_
75-27	13368-13373	under	_
75-28	13374-13387	consideration	_
75-29	13388-13391	and	_
75-30	13392-13395	the	_
75-31	13396-13400	time	_
75-32	13401-13407	course	_
75-33	13408-13410	of	_
75-34	13411-13414	the	_
75-35	13415-13418	RSN	_
75-36	13419-13422	and	_
75-37	13423-13434	transferred	_
75-38	13435-13437	to	_
75-39	13438-13446	z-scores	_
75-40	13447-13450	for	_
75-41	13451-13456	every	_
75-42	13457-13468	participant	_
75-43	13469-13470	.	_

76-1	13471-13475	Then	_
76-2	13476-13477	,	_
76-3	13478-13481	the	_
76-4	13482-13484	FC	_
76-5	13485-13493	measures	_
76-6	13494-13498	were	_
76-7	13499-13507	compared	_
76-8	13508-13515	between	_
76-9	13516-13527	individuals	_
76-10	13528-13532	with	_
76-11	13533-13536	NUD	_
76-12	13537-13540	and	_
76-13	13541-13552	non-smoking	_
76-14	13553-13561	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
76-15	13562-13563	.	_

77-1	13564-13567	The	_
77-2	13568-13579	statistical	_
77-3	13580-13589	threshold	_
77-4	13590-13593	was	_
77-5	13594-13597	two	_
77-6	13598-13604	sample	_
77-7	13605-13612	t-tests	_
77-8	13613-13614	,	_
77-9	13615-13621	p=0.05	_
77-10	13622-13623	,	_
77-11	13624-13627	FDR	_
77-12	13628-13629	(	_
77-13	13630-13635	false	_
77-14	13636-13645	discovery	_
77-15	13646-13650	rate	_
77-16	13651-13652	)	_
77-17	13653-13662	corrected	_
77-18	13663-13664	.	_

